The non-alcoholic steatohepatitis (NASH) clinical development field is crowded with various players, targets and therapeutic approaches, but privately held Cirius Therapeutics Inc. thinks it may have a winner as its second-generation thiazolidinedione MSDC-0602K has shown ability to reduce liver enzymes and improve glycemic control with a good safety profile in a Phase IIb interim look.
Designed by Cirius co-founder and Vice President-R&D Jerry Colca to offer the insulin-sensitizing benefits of first-generation TZDs like Takeda Pharmaceutical Co. Ltd